written on 11.03.2014
Tags:
,

SMC recommends six products but rejects two for diabetes

TAGS: ,

The SMC noted that: "The availability of afatinib will provide clinicians and patients with an additional TKI for use in the treatment of EGFR mutation positive NSCLC."

Latest Report